BioTuesdays

Category - Markets

Gritstone Oncology
Markets

BTIG cuts Gritstone Oncology PT to $17 from $31

BTIG reduced its price target for Gritstone Oncology (NASDAQ:GRTS) to $17 from $31, citing interim results from two Phase 1 clinical trials, GRANITE and SLATE, evaluating personalized and off-the-shelf neoantigen...

July 14, 2020
Vapotherm Logo
Markets

BTIG ups Vapotherm PT to $53 from $32

BTIG raised its price target for Vapotherm (NASDAQ:VAPO) to $53 from $32, citing a higher compound annual growth rate for revenue after a proprietary survey of U.S. hospitals that purchased the company’s Precision Flow...

July 13, 2020
BioLife Logo
Markets

Maxim ups Biolife Solutions PT to $26 from $18

Maxim Group raised its price target for Biolife Solutions (NASDAQ:BLFS) to $26 from $18, citing a strengthening balance sheet, with management continuing to execute on its growth strategy. The stock closed at $17.59 on...

July 8, 2020
Markets

Maxim starts TFF Pharma at buy; PT $12

Maxim Group launched coverage of TFF Pharmaceuticals (NASDAQ:TFFP) with a “buy” rating and $12 price target. The stock closed at $6.22 on July 7. The company is using its thin film freezing (TFF) platform to develop two...

July 8, 2020
Markets

Chardan starts NGM Biopharmaceuticals at buy; PT $40

Chardan Capital Markets launched coverage of NGM Biopharmaceuticals (NASDAQ:NGM) with a “buy” rating and $40 price target. The stock closed at $19.01 on July 6. “We anticipate that NGM’s aldafermin is likely to...

July 7, 2020
Organigram
Markets

AGP starts Organigram at buy; PT $4

Alliance Global Partners initiated coverage of Organigram Holdings (TSX:OGI) with a “buy” rating and price target of $4 (Canadian). The stock closed at $2.11 on July 6. “We view Organigram’s low-cost indoor [cannabis]...

July 7, 2020
Markets

Chardan starts Akero Therapeutics at buy; PT $79

Chardan Capital Markets launched coverage of Akero Therapeutics (NASDAQ:AKRO) with a “buy” rating and $79 price target. The stock closed at $34.96 on July 6. “We expect that Akero’s lead asset, efruxifermin, has...

July 7, 2020

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.